S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
NASDAQ:CTIC

CTI BioPharma (CTIC) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$9.09
$9.09
50-Day Range
$8.91
$9.10
52-Week Range
$4.01
$9.10
Volume
N/A
Average Volume
4.50 million shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.75

CTI BioPharma MarketRank™ Forecast

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
7.3% Upside
$9.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.25) to $0.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.79 out of 5 stars

Medical Sector

963rd out of 969 stocks

Pharmaceutical Preparations Industry

448th out of 452 stocks


CTIC stock logo

About CTI BioPharma (NASDAQ:CTIC) Stock

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.


CTIC Stock News Headlines

Top Analyst Exposes Imminent Crisis Hurtling Towards America
The man who warned of the dot-com blow up, the 2008 housing collapse, and the loss of America’s AAA rating makes a shocking prediction…
Sobi completes acquisition of CTI BioPharma Corp.
Stifel Nicolaus upgrades CTI BioPharma (CTIC) to a Hold
Top Analyst Exposes Imminent Crisis Hurtling Towards America
The man who warned of the dot-com blow up, the 2008 housing collapse, and the loss of America’s AAA rating makes a shocking prediction…
JMP Securities Keeps Their Hold Rating on CTI BioPharma (CTIC)
SVB Securities downgrades CTI BioPharma (CTIC) to a Hold
The Latest Analyst Ratings for CTI BioPharma
Why Shares of CTI BioPharma Are Soaring Wednesday
Why Is CTI BioPharma (CTIC) Stock Up 85% Today?
See More Headlines
Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Company Calendar

Last Earnings
3/06/2023
Today
10/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTIC
Previous Symbol
NASDAQ:CTICD
Employees
127
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$9.75
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+7.3%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
7 Analysts

Profitability

Net Income
$-92,990,000.00
Pretax Margin
-91.38%

Debt

Sales & Book Value

Annual Sales
$53 million
Book Value
($0.14) per share

Miscellaneous

Free Float
121,844,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
0.83

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Adam R. Craig M.B.A. (Age 57)
    M.D., Ph.D., Pres, CEO, Interim Chief Medical Officer & Director
    Comp: $1.09M
  • Mr. David H. Kirske (Age 69)
    Exec. VP, CFO & Sec.
    Comp: $590.41k
  • Mr. James K. Fong (Age 61)
    Exec. VP & Chief Commercial Officer
    Comp: $597.3k
  • Mr. Ed Bell
    Sr. Director of Investor Relations
  • Mr. Bruce K. Bennett Jr. (Age 71)
    Sr. VP Global Pharmaceutical Operations
  • Mr. John P. Volpone
    Exec. VP & Chief of Staff
  • Dr. Jennifer A. Smith
    Sr. VP of Biometrics













CTIC Stock - Frequently Asked Questions

Should I buy or sell CTI BioPharma stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CTIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTIC, but not buy additional shares or sell existing shares.
View CTIC analyst ratings
or view top-rated stocks.

What is CTI BioPharma's stock price forecast for 2023?

7 Wall Street research analysts have issued 12 month price objectives for CTI BioPharma's stock. Their CTIC share price forecasts range from $8.00 to $13.00. On average, they expect the company's share price to reach $9.75 in the next year. This suggests a possible upside of 7.3% from the stock's current price.
View analysts price targets for CTIC
or view top-rated stocks among Wall Street analysts.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) posted its earnings results on Monday, March, 6th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. The biopharmaceutical company had revenue of $21.08 million for the quarter, compared to analyst estimates of $24.88 million. During the same period in the prior year, the business earned ($0.38) earnings per share.

When did CTI BioPharma's stock split?

CTI BioPharma's stock reverse split on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is James A. Bianco's approval rating as CTI BioPharma's CEO?

8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of CTI BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $9.09.

How much money does CTI BioPharma make?

CTI BioPharma (NASDAQ:CTIC) has a market capitalization of $1.20 billion and generates $53 million in revenue each year. The biopharmaceutical company earns $-92,990,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.

How many employees does CTI BioPharma have?

The company employs 127 workers across the globe.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The official website for the company is www.ctibiopharma.com. The biopharmaceutical company can be reached via phone at (206) 282-7100, via email at invest@ctibiopharma.com, or via fax at 206-284-6206.

This page (NASDAQ:CTIC) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -